Activity Overview
Over the past decade, oncology has begun to leverage a rapidly maturing effort to target the KRAS protein in RAS-altered cancers. This has led to the introduction of targeted therapies with the potential to offer unprecedented benefit to patients. Still, these agents differ greatly in their mechanisms of action, relevant alterations, and adverse event profiles.
In this module, David Hong explains the mechanisms of action of RAS/MAPK inhibitors approved or being investigated for patients with different forms of cancer, as well as how these agents fit into the paradigm of management of RAS-altered cancers.
Target Audience
This activity is directed toward medical oncologists, molecular pathologists, and other oncology health care professionals
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the role of KRAS/RAS mutations in solid tumors

David S. Hong MD
Douglas E. Johnson Endowed Professor
Deputy Chair of the Department of Investigational Cancer Therapeutics [A Phase I Program]
Division of Cancer Medicine
Clinical Medical Director of the Clinical and Translational Research Center (CTRC)
University of Texas M.D. Anderson Cancer Center
Houston, TX
Disclosures: Consulting, Speaker, or Advisory Role: AbbVie, Acuta, Adlai-Nortye, Alpha Insights, Amgen, Arkin, Axiom, BeiGene, Blueprint, Boxer Capital, BVF Advisory and Consulting, ClearView Oncology, Cogent Therapeutics, COR2ed, CureBio, Ecor1, Erasca, Fortress Biotech, GLG, Guidepoint, HUYABIO, ImmunoGenesis, Kanaph Therapeutics, Kayak Therapeutics, Kestrel Therapeutics, Medscape, Morgan-Stanley, Nextech Ventures, Pfizer, PharmaResearch, Pre-Amp, Revolution Medicine, T-Knife, WebMD; Other ownership interests: BreakThrough Bio (Advisor), Molecular Match (Advisor), OncoResponse (Founder, Advisor), Telperian (Founder, Advisor), Interact Therapeutics (Advisor); Research/Grant Funding (to institution): AbbVie, Acendo, Adagene, Adaptimmune, Adlai-Nortye, Alterome, Amgen, Arvinas, AstraZeneca, Bayer, BeiGene USA, BluePrint, Bridge-Bio, Bristol Myers Squibb, Chong Kun, D3 Bio, Deciphera, Eli Lilly, Endeavor, Erasca, Exelixis Inc., F. Hoffmann-LaRoche/Genentech, Immunogenesis, Inhibrix, Kestrel, Kumquat, KURA, NCI-CTEP, Pfizer, Quanta Therapeutics, Revolution Medicine, VelaVagio, Verastem, VM Oncology; Travel, Accommodations, Expenses: AACR, Immunogenesis, Medscape, Telperian
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here